Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection

被引:41
作者
Brown, FG
Nikolic-Paterson, DJ
Chadban, SJ
Dowling, J
Jose, M
Metz, CN
Bucala, R
Atkins, RC
机构
[1] Monash Med Ctr, Dept Nephrol, Clayton, Vic 3168, Australia
[2] Monash Med Ctr, Dept Anat, Clayton, Vic 3168, Australia
[3] Monash Univ, Dept Med, Clayton, Vic 3168, Australia
[4] Picower Inst Med Res, Manhasset, NY 11030 USA
关键词
D O I
10.1097/00007890-200106270-00013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that is a potent activator of macrophages and T cells. Previous studies have shown that local MIF production is increased in acute renal allograft rejection, suggesting that it may play an important role in the rejection process, Aims. To determine if urine and serum MIF concentrations: (1) are increased in acute rejection, and (2) can be used as noninvasive tools to discriminate between acute rejection (AR) and cyclosporine nephrotoxicity (CyA toxicity). Methods. In a prospective study of nine renal allograft patients (five acute rejection and four stable), serial urine MIF concentrations were measured by ELISA in the first 14 days after transplantation. In a retrospective study, MIF concentrations in urine and serum were measured in 24 patients who were biopsied for acute renal transplant dysfunction (11 AR, 13 CyA toxicity). Urine and serum MIF were also measured in 23 stable renal transplant patients and 10 normals. Results, MIF was readily detected in the urine of normal healthy controls (106+/-61 pg/mu mol creatinine), In the prospective study, the urinary MIF concentration was increased substantially on day 1 posttransplantation and subsequently fell in parallel with the serum creatinine, However, urine MIF increased before episodes of biopsy proven acute rejection. The retrospective study showed that urine MIF concentrations in patients with AR were increased 5-fold compared to normal controls (439+/-313 pg/mu mol Cr; P<0.01). In contrast, urine MIF concentrations in CyA toxicity were not significantly different to normal controls (145+/-119 pg/<mu>mol Cr; P=NS), A marked increase in MIF immunostaining was seen in biopsies of AR, but not in CyA toxicity. No significant differences were evident in serum MIF levels between normals and any transplant patient group. Conclusions. These results suggest that measurement of urine MIF concentration may be useful in monitoring renal transplant patients for acute rejection and as a discriminator from cyclosporine nephrotoxicity.
引用
收藏
页码:1777 / 1783
页数:7
相关论文
共 26 条
  • [1] An essential regulatory role for macrophage migration inhibitory factor in T-cell activation
    Bacher, M
    Metz, CN
    Calandra, T
    Mayer, K
    Chesney, J
    Lohoff, M
    Gemsa, D
    Donnelly, T
    Bucala, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7849 - 7854
  • [2] Bacher M, 1997, AM J PATHOL, V150, P235
  • [3] MIF IS A PITUITARY-DERIVED CYTOKINE THAT POTENTIATES LETHAL ENDOTOXEMIA
    BERNHAGEN, J
    CALANDRA, T
    MITCHELL, RA
    MARTIN, SB
    TRACEY, KJ
    VOELTER, W
    MANOGUE, KR
    CERAMI, A
    BUCALA, R
    [J]. NATURE, 1993, 365 (6448) : 756 - 759
  • [4] PURIFICATION, BIOACTIVITY, AND SECONDARY STRUCTURE-ANALYSIS OF MOUSE AND HUMAN MACROPHAGE-MIGRATION INHIBITORY FACTOR (MIF)
    BERNHAGEN, J
    MITCHELL, RA
    CALANDRA, T
    VOELTER, W
    CERAMI, A
    BUCALA, R
    [J]. BIOCHEMISTRY, 1994, 33 (47) : 14144 - 14155
  • [5] An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction
    Bernhagen, J
    Bacher, M
    Calandra, T
    Metz, CN
    Doty, SB
    Donnelly, T
    Bucala, R
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) : 277 - 282
  • [6] MECHANISM OF A REACTION IN VITRO ASSOCIATED WITH DELAYED-TYPE HYPERSENSITIVITY
    BLOOM, BR
    BENNETT, B
    [J]. SCIENCE, 1966, 153 (3731) : 80 - &
  • [7] Brown FG, 1999, CLIN EXP IMMUNOL, V118, P329
  • [8] MACROPHAGE IS AN IMPORTANT AND PREVIOUSLY UNRECOGNIZED SOURCE OF MACROPHAGE-MIGRATION INHIBITORY FACTOR
    CALANDRA, T
    BERNHAGEN, J
    MITCHELL, RA
    BUCALA, R
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (06) : 1895 - 1902
  • [9] Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria
    Calandra, T
    Spiegel, LA
    Metz, CN
    Bucala, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (19) : 11383 - 11388
  • [10] Protection from septic shock by neutralization of macrophage migration inhibitory factor
    Calandra, T
    Echtenacher, B
    Le Roy, D
    Pugin, J
    Metz, CN
    Hültner, L
    Heumann, D
    Männel, D
    Bucala, R
    Glauser, MP
    [J]. NATURE MEDICINE, 2000, 6 (02) : 164 - 170